Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia

Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia

Background: Despite the success of current treatments, many chronic hepatitis B (CHB) patients still live with low-level viremia [LLV] resulting in liver disease progression. This study evaluated the long-term health and economic impact of switching to tenofovir alafenamide (TAF) from entecavir (ETV...

Full description

Bibliographic Details
Main Authors: Faisal M Sanai, Mohammed Aljawad, Abdullah Saeed Alghamdi, Alon Yehoshua, Abdullah Khathlan, Mohammed Alghamdi, Sam Kozma, Nathaniel Smith, Fadoua El-Moustaid, Sushanth Jeyakumar, Nandita Kachru
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-01-01
Series:The Saudi Journal of Gastroenterology
Subjects:
chronic hepatitis b
cost-effectiveness
markov state-transition model
tenofovir alafenamide
Online Access:http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2024;volume=30;issue=1;spage=23;epage=29;aulast=Sanai

Internet

http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2024;volume=30;issue=1;spage=23;epage=29;aulast=Sanai

Similar Items